
---
title: '莱美药业：拟签署《醋酸曲普瑞林注射液产品权利转让协议》'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=5239'
author: 证券时报网
comments: false
date: Mon, 01 Aug 2022 18:18:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=5239'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300006" style="color: #2f67d1;text-decoration: none;" code="300006" target="_blank">莱美药业</a>(300006)8月1日晚间公告，拟与<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002693" style="color: #2f67d1;text-decoration: none;" code="002693" target="_blank">双成药业</a>和杭州博盈签署《醋酸曲普瑞林注射液产品权利转让协议》。拟以2880万元受让<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002693" style="color: #2f67d1;text-decoration: none;" code="002693" target="_blank">双成药业</a>获得上市许可后的与醋酸曲普瑞林注射液在指定区域有关的所有的有形与无形资产、权利。醋酸曲普瑞林注射液适用于不育治疗下所需的垂体降调节。</p>

                  
</div>
            